Drug Information

Drug General Information
Drug ID
D0S4II
Former ID
DCL000407
Drug Name
GSK1292263
Drug Type
Small molecular drug
Indication Gastric cancer; Type 2 diabetes [ICD9: 151, 250; ICD10:C16, E11] Phase 2 [523205]
Company
GSK
Formula
C24H30N4O4S
Canonical SMILES
CC(C)C1=NOC(=N1)N2CCC(CC2)CCOC3=CN=C(C=C3)C4=CC=C(C=C4)<br />S(=O)(=O)C
InChI
1S/C24H30N4O4S/c1-17(2)23-26-24(32-27-23)28-13-10-18(11-14-28)12-15-31-20-6-9-22(25-16-20)19-4-7-21(8-5-19)33(3,29)30/h4-9,16-18H,10-15H2,1-3H3
InChIKey
HWRHYSUKHZYCAU-UHFFFAOYSA-N
PubChem Compound ID
71301143
Target and Pathway
Target(s) Glucose-dependent insulinotropic receptor Target Info Modulator
KEGG Pathway cAMP signaling pathway
Insulin secretion
WikiPathways Incretin Synthesis, Secretion, and Inactivation
References
Ref 523205ClinicalTrials.gov (NCT01218204) A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin.U.S. National Institutes of Health.